GAMMA Investing’s Rapport Therapeutics RAPP Stock Holding History

GAMMA Investing’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$18.1K	Buy	539 +131	+32%	+$5.66K	﹤0.01%	3005
2026 Q2	$17K	Buy	408 +30	+8%	+$1.1K	﹤0.01%	2934
2026 Q1	$11.8K	Buy	378 +36	+11%	+$1.01K	﹤0.01%	2984
2025 Q4	$10.4K	Sell	342 -12	-3%	-$332	﹤0.01%	2962
2025 Q3	$10.5K	Sell	354 -91	-20%	-$1.62K	﹤0.01%	2861
2025 Q2	$5.06K	Sell	445 -473	-52%	-$5.02K	﹤0.01%	3109
2025 Q1	$9.21K	Buy	918 +908	+9,080%	+$11.8K	﹤0.01%	2784
2024 Q4	$177	Buy	+10	New	+$222	﹤0.01%	3717

Other funds holding RAPP

CPW

Catalyst Private Wealth San Mateo, California $239M AUM 21.76% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's RAPP Position: Q3 2026 in Review

GAMMA Investing increased its Rapport Therapeutics (RAPP) stake by 32% in Q3 2026, buying an estimated $5.66K and bringing the position to 539 shares worth $18.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3005.

GAMMA Investing first reported a position in RAPP in Q4 2024 and has held it in 8 quarters since. 8 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

GAMMA Investing held 539 shares of Rapport Therapeutics worth $18.1K as of Q3 2026.
GAMMA Investing bought 131 Rapport Therapeutics shares in Q3 2026, an estimated $5.66K.
Rapport Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3005 holding.
GAMMA Investing first reported a position in Rapport Therapeutics in Q4 2024 and has held it in 8 quarters since.
8 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.